Previous 10 | Next 10 |
2023-08-11 09:56:13 ET Vor Biopharma press release ( NASDAQ: VOR ): Q2 GAAP EPS of -$0.45 beats by $0.03 . Cash, cash equivalents and marketable securities were $186.9 million as of June 30, 2023, which is projected to fund operations into the first quarter of 2025. ...
Next trem-cel clinical data update expected by year-end 2023 VCAR33 ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiation Secured non-exclusive license to Cas9 gene-edited HSCs CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE...
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow Healthcare Conference. Wedbush PacGrow Healthcare Conference 1x1 Investor Meetings: Au...
2023-07-18 17:26:50 ET Gainers: Ribbon Communications ( NASDAQ: RBBN ) +7% . Terns Pharmaceuticals ( TERN ) +3% . Arrival ( ARVL ) +3% . EyePoint Pharmaceuticals ( EYPT ) +3% . Lyra Therapeutics ( LYRA ) +3% . ...
P atients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimeris m . Strong investigator enthusiasm and continued robust enrollment; additional data updates expected by year-end 2023 ...
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman Sachs 44th Annual Global Healthcare Conference. Goldman Sachs 44th Annual Global Healthcare...
2023-05-11 17:02:51 ET Vor Biopharma press release ( NASDAQ: VOR ): Q1 GAAP EPS of -$0.43 misses by $0.05 . Cash, cash equivalents and marketable securities were $210.2 million as of March 31, 2023, which is projected to fund operations into the first quarter of 2025. ...
VBP101 clinical data update planned at European Hematology Association (EHA) 2023 VCAR33 ALLO IND submission on-track for 1H 2023 CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today repor...
2023-04-21 15:00:36 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
2023-03-27 15:13:57 ET Summary Vor Biopharma Inc. is the brainchild of Dr. Siddhartha Mukherjee. Its core idea is to make CAR-Ts safer by using stem cells. I must admit the idea is interesting, and I would like to see more data from this company. If you are buying Vo...
News, Short Squeeze, Breakout and More Instantly...
On-track for trem-cel and VCAR33 ALLO clinical updates in the second half of 2024 Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWI...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint M...
Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March...